Johnson & Johnson receives U.S. FDA Priority Review for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic castration-sensitive prostate cancer

Written by

in

HORSHAM, PA, October 16, 2025 – The U.S. Food and Drug Administration (FDA) granted Priority Review to Johnson & Johnson for its supplemental New Drug Application (sNDA) for AKEEGA^® (niraparib and abiraterone…

Continue Reading

More posts

New Onset Hypertension Following COVID-19 Among Aseer Residents, Kingd

October 25, 2025
London Underground mosquito’s origins traced to ancient Egypt

October 25, 2025
iScanner’s lifetime plan for $25

October 25, 2025
Degenerative rotator cuff tears in correlation with different anatomic shoulder parameters on MRI | Egyptian Journal of Radiology and Nuclear Medicine

October 25, 2025